Medical Access in Portugal

Currently classified in Portugal under the national drug scheduling framework and not authorised for routine medical treatment; authorised access is limited to approved clinical research programmes. Decree‑Law n.º 15/93 lists psychotropic substances under national control and, together with Law n.º 30/2000 (the 2000 decriminalisation law), creates the framework where personal possession may be decriminalised but distribution, manufacture and medical authorisation require a formal regulatory pathway [1]Decree‑Law 15/93 [2]Law 30/2000 – decriminalisation context. Ongoing international phase‑2/3 research programs (and Portuguese interest in trials) mean clinical access in Portugal is possible only inside approved studies; there is no national marketing authorisation or routine public reimbursement for psilocybin products as of the Infarmed publications and legal framework above.

MDMA remains a controlled psychotropic substance under Decree‑Law n.º 15/93 and has no authorised medical marketing authorisation in Portugal for routine clinical use; authorised access is limited to approved clinical research. International phase‑3 PTSD programmes are ongoing and have generated regulatory submissions elsewhere, but in Portugal clinical availability of MDMA‑assisted therapy is restricted to formally approved research protocols and not reimbursed by the national health system. Citations: national scheduling and regulatory context. [1]Decree‑Law 15/93 [2]Law 30/2000.

Esketamine (Spravato) is an authorised medicinal product in the EU (EMA product page describes indication and supervised‑use requirements) and has been the subject of an Infarmed public funding/financing assessment for Portugal. The European Medicines Agency summarises the authorised indication (treatment‑resistant major depressive disorder in adults, given under supervision) and the safety/monitoring constraints for clinic administration. [1]EMA Spravato EPAR.

In Portugal, Infarmed conducted a public evaluation of Spravato and issued a funding/financing assessment decision in 2025: Infarmed's public documentation records an evaluation and deferment decision regarding Spravato (esketamine) for use in hospital settings for adults with treatment‑resistant major depressive disorder, and notes the specific clinical criteria tied to the funding decision (treatment‑resistant cases, prior therapeutic steps including psychotherapy/electroconvulsive therapy considerations, and administration in a controlled hospital environment). The Infarmed evaluation and public report are the authoritative national source on pricing and public financing for this medicinal product in Portugal. [2]INFARMED public documentation – Spravato financing evaluation.

Practical reimbursement/access implications: the Infarmed decision (May 2025) made Spravato available for use in hospital settings under the specified indication and conditions; delivery is under strict clinic supervision and typically requires hospital infrastructure (blood‑pressure monitoring, emergency readiness). Public reimbursement applies according to the Infarmed financing decision and hospital‑level implementation rules (i.e., use in accredited hospital units and subject to the conditions described in the Infarmed report). For completeness, clinicians and hospitals must follow Infarmed's published protocol/decision when implementing access and any local hospital formularies or regional health administration may define implementation details.

Ketamine is a licensed anaesthetic and an established medicinal product for anaesthesia and analgesia; its intravenous and intranasal formulations are used off‑label in many jurisdictions (including Portugal) for management of severe or treatment‑resistant depression under clinical protocols. In Portugal there is documented clinical use and active professional discussion about structured ketamine programmes: peer‑reviewed Portuguese surveys and professional society activity describe protocols, hospital pilot programmes and private clinic offerings for ketamine in depression (use is typically off‑label and requires institutional protocol/psychiatric oversight) [1]Study on Portuguese clinicians' attitudes to ketamine [2]Portuguese reporting on ketamine and psychedelics in mental health.

Reimbursement: as an off‑label psychiatric intervention, routine public reimbursement by the SNS is not guaranteed and depends on local hospital procurement, inclusion in a hospital protocol and case‑by‑case decisions; many treatments have been delivered in private clinics (self‑pay) or through hospital pilot programmes. The professional and regulatory expectation in Portugal is that ketamine therapy for depression be delivered under defined protocols with psychiatric oversight, informed consent, and appropriate monitoring; patients should check hospital/regional policies and private clinic conditions for cost/reimbursement specifics.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT and its salts appear in the national schedules (Decree‑Law n.º 15/93) and any possession/distribution beyond decriminalised personal‑use thresholds is a criminal or administrative offence; clinical/research access requires formal regulatory approvals. [1]Decree‑Law 15/93 [2]Law 30/2000.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Like other substituted tryptamines, 5‑MeO‑DMT is covered by national scheduling and is not available for routine therapeutic use in Portugal outside of authorised research settings. [1]Decree‑Law 15/93.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no established medical authorisation or routine reimbursement for ibogaine in Portugal; any investigational use would require regulatory approvals and ethics committee oversight. [1]Decree‑Law 15/93.

Ayahuasca occupies a legal grey area in Portugal: the active alkaloid (DMT) is controlled under Decree‑Law n.º 15/93, but possession/use for personal consumption is decriminalised under Law n.º 30/2000; consequently some retreats and religious ceremonies operate in Portugal in a legally ambiguous environment. Legal commentary and NGO analyses note that while DMT is a scheduled substance, the constitutional protections for religious practice and the decriminalisation of personal use create interpretive complexity — distribution, importation and commercial supply remain legally risky without specific authorisations. In practice, some groups and retreat providers operate discreetly and religious communities have sought recognition, but consistent formal legal authorisation for ayahuasca sacramental use is not established nationwide. [1]Decree‑Law 15/93 [2]ICEERS analysis – ayahuasca legal clarity in Portugal [3]Law 30/2000.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti are controlled under the national schedules; distribution and commercial supply are prohibited absent explicit regulatory authorisation for research. [1]Decree‑Law 15/93.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The family of substituted phenethylamines (including 2C‑series compounds where specifically scheduled) is controlled under the Decree‑Law; there is no routine medical access or reimbursement. [1]Decree‑Law 15/93.